OLEMA PHARMACEUTICALS INC (OLMA) Stock Earnings & Estimates
USA - NASDAQ:OLMA - US68062P1066 - Common Stock
22.01 USD
+2.58 (+13.28%)
22.1 USD
+0.09 (+0.41%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A 769.23% | N/A 412.95% | N/A 96.23% | N/A 67.43% | N/A 67.39% | N/A 33.45% | ||||||||
| EBITDA YoY % growth | -2.07M | -4.31M -108.21% | -21.52M -399.30% | -71.33M -231.46% | -106.63M -49.49% | -104.584M 1.92% | -141.865M -35.65% | N/A -13.21% | N/A -19.40% | N/A -10.78% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.08M | -4.32M -107.69% | -21.53M -398.38% | -71.49M -232.05% | -106.99M -49.66% | -104.961M 1.90% | -142.258M -35.53% | N/A -23.00% | N/A -14.37% | N/A -1.99% | N/A 3.41% | N/A 44.65% | N/A 123.59% | N/A 671.00% | N/A 93.01% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | -1.80 -71.33% | -2.62 -45.56% | -2.16 17.56% | -2.21 -2.31% | N/A 15.54% | N/A -20.48% | N/A 4.42% | N/A -6.06% | N/A 17.90% | N/A 29.97% | N/A -35.41% | N/A 71.26% |
All data in USD
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.55 -8.30% | -0.57 -58.10% | -0.60 -17.60% | -0.59 -20.32% | -0.56 -1.57% | -0.72 -26.34% | -0.60 0.17% | -0.63 -6.06% |
| Revenue Q2Q % growth | N/A | N/A | N/A | |||||
| EBITDA Q2Q % growth | -44.399M -22.06% | -43.548M -25.34% | -44.675M 6.15% | -46.409M -19.13% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -49.389M -34.33% | -52.383M -50.21% | -54.618M -14.11% | -54.892M -22.92% | -56.1M -13.59% | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2025 Q2Q % growth | -0.49 18.33% | -0.49 | 0.00 | 0.67% |
| Q2 2025 Q2Q % growth | -0.51 5.56% | -0.38 | -0.13 | -32.98% |
| Q1 2025 Q2Q % growth | -0.36 35.71% | -0.52 | 0.16 | 30.80% |
| Q4 2024 Q2Q % growth | -0.51 -4.08% | -0.65 | 0.14 | 21.88% |
| Q3 2024 Q2Q % growth | -0.60 -25.00% | -0.59 | -0.01 | -1.80% |
| Q2 2024 Q2Q % growth | -0.54 -10.20% | -0.57 | 0.03 | 4.46% |
| Q1 2024 Q2Q % growth | -0.56 20.00% | -0.56 | 0.00 | -0.58% |
| Q4 2023 Q2Q % growth | -0.49 24.62% | -0.49 | 0.00 | 0.10% |
| Q3 2023 Q2Q % growth | -0.48 15.79% | -0.52 | 0.04 | 7.95% |
| Q2 2023 Q2Q % growth | -0.49 40.24% | -0.74 | 0.25 | 33.93% |
| Q1 2023 Q2Q % growth | -0.70 -20.69% | -0.68 | -0.02 | -3.46% |
| Q4 2022 Q2Q % growth | -0.65 -20.37% | -0.67 | 0.02 | 2.26% |
| Q3 2022 Q2Q % growth | -0.57 -26.67% | -0.78 | 0.21 | 27.24% |
| Q2 2022 Q2Q % growth | -0.82 -95.24% | -0.65 | -0.17 | -25.22% |
| Q1 2022 Q2Q % growth | -0.58 -48.72% | -0.58 | 0.00 | 0.24% |
| Q4 2021 Q2Q % growth | -0.54 -8.00% | -0.50 | -0.04 | -6.95% |
| Q3 2021 Q2Q % growth | -0.45 | -0.47 | 0.02 | 3.25% |
| Q2 2021 Q2Q % growth | -0.42 | -0.39 | -0.03 | -8.36% |
| Q1 2021 Q2Q % growth | -0.39 | -0.29 | -0.10 | -36.55% |
| Q4 2020 Q2Q % growth | -0.50 | -0.18 | -0.32 | -177.46% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -0.79% | -10.75% | -0.18% | -7.34% |
| Revenue | N/A | N/A | N/A | N/A |